Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: results from the AIDS clinical trials group study A5095

DOI10.1080/01621459.2011.646932zbMATH Open1328.62591OpenAlexW1981820125WikidataQ36534104 ScholiaQ36534104MaRDI QIDQ4916488FDOQ4916488

Authors: Li Li, Joseph J. jun. Eron, Heather Ribaudo, Roy M. Gulick, Brent A. Johnson 

Publication date: 22 April 2013

Published in: Journal of the American Statistical Association (Search for Journal in Brave)

Full work available at URL: http://europepmc.org/articles/pmc3545451

Recommendations

• Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times
• Viral suppression in HIV studies: combining times to suppression and rebound
• Estimating causal treatment effects from longitudinal HIV natural history studies using marginal structural models
• Impact of time to start treatment following infection with application to initiating HAART in HIV-positive patients
• Doubly robust estimation of optimal treatment regimes for survival data -- with application to an HIV/AIDS study

zbMATH Keywords

causal inferencemissing datadouble robustnessRubin causal modellongitudinal data analysissemiparametric efficient estimation

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Medical applications (general) (92C50)

Cites Work

• A Distributional Approach for Causal Inference Using Propensity Scores
• Semiparametric theory and missing data.
• The central role of the propensity score in observational studies for causal effects
• A new approach to causal inference in mortality studies with a sustained exposure period—application to control of the healthy worker survivor effect
• Marginal Mean Models for Dynamic Regimes
• Comment: Performance of double-robust estimators when ``inverse probability weights are highly variable
• Some results on generalized difference estimation and generalized regression estimation for finite populations
• Estimation of survival distributions of treatment policies in two-stage randomization designs in clinical trials
• Optimal Estimator for the Survival Distribution and Related Quantities for Treatment Policies in Two‐Stage Randomization Designs in Clinical Trials
• Exact Confidence Intervals Following a Group Sequential Test

Cited In (1)

• Modeling clinical endpoints as a function of time of switch to second-line ART with incomplete data on switching times

This page was built for publication: Evaluating the effect of early versus late ARV regimen change if failure on an initial regimen: results from the AIDS clinical trials group study A5095

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4916488)